Thrombosis Model in Mouse Carotid Induced by Guidewire
Thrombosis Model in Mouse Carotid Induced by Guidewire
复制标题
导丝诱导小鼠颈动脉血栓形成模型
DOI：
10.1007/s40846-016-0125-0
复制
发表时间：
2016-04-01
影响因子：
2
通讯作者：
Wang, Guixue
中科院分区：
文献类型：
--
作者：
Huang, Lu;Lei, Daoxi;Wang, Guixue
研究人员已经在老鼠身上建立了许多血栓形成模型。一些建模方法需要专门的设备，且成本较高。本研究建立了一种低成本、易操作、可控性好的小鼠颈动脉损伤血栓模型。用导丝抓伤颈动脉，造成颈动脉浅层损伤。实时观察和记录血栓形成情况。使用Metamorph和Graphpad软件进行血栓形成量化分析。用透射电子显微镜、扫描电子显微镜和苏木精-伊红染色对损伤的血管壁进行组织学分析。将三种临床药物分别应用于该模型进行进一步评价。在此损伤模型中，通过透射电子显微镜观察到内皮细胞被完全去除。剥脱后的表面覆盖有血小板，HE染色及扫描电子显微镜观察聚集体的形成。模型中形成一过性血栓，于伤后1min左右达高峰，3min内逐渐消失。在这个模型中，临床药物的使用减少了血栓的形成。所有皮损对血小板GPIIb-IIIa、P2Y12抑制和凝血酶阻断均敏感。该模型具有良好的重复性和可行性，可用于治疗靶向和抗血栓药物的筛选。
Researchers have developed many thrombosis models in the mouse. Some methods for establishing the model require specialized equipment and have high cost. The present study develops a low-cost, easy-to-operate, and well-controlled vascular injury thrombosis model in the mouse carotid artery induced by a guidewire. Superficial injury was induced in the carotid artery by scratching with a guidewire. Thrombus formation was observed and recorded in real time. Thrombosis quantification analyses were performed using Metamorph and Graphpad software. Transmission electron microscopy (TEM), scanning electron microscopy (SEM), and hematoxylin and eosin (HE) staining were employed for the histological analysis of the injured vessel wall. Three clinical drugs were respectively administrated to this model for further evaluation. Complete removal of the endothelium was observed by TEM in this injury model. Platelets covered the denuded surface, in which the aggregates were detected by HE staining and SEM. A transient thrombus reaching peak at around 1 min after injury and vanishing gradually within 3 min formed in the model. Administration of clinical medicaments decreased thrombus formation in this model. All lesions were sensitive to platelet GPIIb-IIIa, P2Y12 inhibition, and thrombin blockade. The proposed model has good reproducibility and feasibility and could be applied in therapeutic targeting and anti-thrombotic drug screening.